1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Sweden Pharmaceuticals and Healthcare Report Q4 2016

Sweden Pharmaceuticals and Healthcare Report Q4 2016

  • September 2016
  • -
  • Business Monitor International
  • -
  • 98 pages

Includes 3 FREE quarterly updates

BMI View:

Declining government reimbursement for prescription medicines and the promotion of lowervaluegeneric medicines does not bode well for innovative drugmakers selling their products in Sweden,particularly as the government is the primary purchaser of pharmaceuticals. Over the long term, pushingcosts onto a population with fewer young people to financially support the elderly will ultimately work toreduce the consumption of higher-value innovative pharmaceuticals.

Headline Expenditure Projections

- Pharmaceuticals: SEK39.50bn (USD4.68bn) in 2015 to SEK39.69bn (USD4.67bn) in 2016; +0.48% inlocal currency terms and -0.4% in US dollar terms.

- Healthcare: SEK376.26bn (USD44.62bn) in 2015 to SEK385.99bn (USD45.39bn) in 2016; +2.6% inlocal currency terms and 1.7% in US dollar terms.Risk/Reward IndexIn BMI's Q416 Risk/Rewards Index, Sweden ranks tenth in the region. Factors such as the country's highper capita incomes and strong regulatory foundations will continue to promote per capita spending onpharmaceuticals and healthcare in general. However, the downward pressure on pharmaceutical prices willcontinue to be acutely felt in this small market of fewer than 10mn people.Latest Updates

- According to LIF, the collective revenue generated by the top 15 pharmaceutical companies in Swedenincreased from SEK17.42bn (USD2.08bn) in 2014 to SEK19.55bn (USD2.34bn) in 2015, with 13 of the15 companies recording increases in revenues.

- According to LIF, the collective revenue generated by the top 15 medicines experienced a 22.5% increasein 2015 - boosted by the commercialisation of Sovaldi, Harvoni and Daklinza in Sweden.

- In July 2016, it was reported that Sweden has entered the race to succeed the UK as the host of theEuropean Union's medicines agency in the aftermath of the Brexit vote.

Table Of Contents

Sweden Pharmaceuticals and Healthcare Report Q4 2016
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Sweden 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Sweden 2012-2020) 12
Healthcare Market Forecast 14
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Sweden 2012-2020) 16
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Sweden 2012-2020) 16
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Sweden 2012-2020) 17
Prescription Drug Market Forecast 18
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Sweden 2012-2020) 19
Patented Drug Market Forecast 20
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Sweden 2012-2020) 21
Generic Drug Market Forecast 22
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Sweden 2012-2020) 23
OTC Medicines Market Forecast 24
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Sweden 2012-2020) 25
Pharmaceutical Trade Forecast 26
Table: Pharmaceutical Trade Data And Forecasts (Sweden 2014-2020) 27
Table: Pharmaceutical Trade Data And Forecasts local currency (Sweden 2014-2020) 28
Industry Risk/Reward Index 29
Western Europe Risk/Reward Index 29
Sweden Risk/Reward Index 35
Rewards 35
Risks 35
Regulatory Review 37
Intellectual Property Issues 38
Pricing Regime 39
Reimbursement Regime 41
Market Overview 43
Healthcare Sector 43
Table: Healthcare Resources (Sweden 2010-2015) 49
Table: Healthcare Personnel (Sweden 2010-2015) 49
Table: Healthcare Activity (Sweden 2010-2015) 50
Research and Development 50
Table: Drug Development Member Companies of SwedenBIO, 2015 51
Clinical Trials 52
Epidemiology 53
Competitive Landscape 57
Research-Based Industry 57
Table: Multinational Market Activity 59
Pharmaceutical Distribution 60
Pharmaceutical Retail Sector 61
Company Profile 63
AstraZeneca 63
Meda 68
Medivir 73
Novartis 78
Swedish Orphan Biovitrum (SOBI) 81
Demographic Forecast 87
Sweden Demographic Forecast 87
Table: Population Headline Indicators (Sweden 1990-2025) 88
Table: Key Population Ratios (Sweden 1990-2025) 88
Table: Urban/Rural Population and Life Expectancy (Sweden 1990-2025) 89
Table: Population By Age Group (Sweden 1990-2025) 89
Table: Population By Age Group % (Sweden 1990-2025) 90
Glossary 92
Methodology 94
Pharmaceutical Expenditure Forecast Model 94
Healthcare Expenditure Forecast Model 94
Notes On Methodology 95
Risk/Reward Index Methodology 96
Index Overview 97
Table: Pharmaceutical Risk/Reward Index Indicators 97
Indicator Weightings 98

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.